Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
33 hedge funds and large institutions have $28.5M invested in Agile Therapeutics in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
38% more funds holding
Funds holding: 24 → 33 (+9)
7% more capital invested
Capital invested by funds: $26.7M → $28.5M (+$1.84M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$2.83M |
| 2 |
DM
Deerfield Management
New York
|
+$1.96M |
| 3 |
EP
Eversept Partners
New York
|
+$1.12M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$727K |
| 5 |
6CM
683 Capital Management
New York
|
+$463K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$2.21M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$580K |
| 3 |
JP Morgan Chase
New York
|
-$108K |
| 4 |
NIM
Needham Investment Management
New York
|
-$49.3K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$22.2K |
AGRX Hedge Fund Activity: Q3 2019 in Review
33 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q3 2019, worth a combined $28.5M — up 6.9% from $26.7M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AGRX positions and 5 closed out — a net gain of 10 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $2.83M. The largest seller was Vivo Capital, exiting entirely with an estimated $2.21M sold.
- 33 institutional investors held Agile Therapeutics (AGRX) as of Q3 2019, up from 24 in Q2 2019.
- Funds reported $28.5M of Agile Therapeutics stock for Q3 2019, up 6.9% quarter-over-quarter.
- 15 funds opened new Agile Therapeutics positions in Q3 2019 and 5 closed out, a net change of +10 holders.
- The largest Agile Therapeutics buyer in Q3 2019 was Perceptive Advisors, an estimated $2.83M added.
- The largest Agile Therapeutics seller in Q3 2019 was Vivo Capital, an estimated $2.21M sold.
Based on aggregated 13F filings for Q3 2019.